Please login to order a test.
VistaSeq℠ Hereditary Cancer Panel Without BRCA
The following genes are assessed: APC, ATM, BARD1, BMPR1A, BRIP1, CDH1, CDK4, CDKN2A, CHEK2, EPCAM, FAM175A, MLH1, MSH2, MSH6, MUTYH, NBN, PALB2, PMS2, PRKAR1A, PTEN, RAD51C, RAD51D, SMAD4, STK11, TP53.
The VistaSeq℠ Hereditary Cancer Panel Without BRCA provides an assessment of inherited genetic mutations within a panel of 25 genes known to be associated with hereditary cancer syndromes. The test is intended for individuals who have already had a BRCA1 and BRCA2 gene assessment, but for whom results of that testing were negative and/or personal or family history warrant assessment of additional genes.
Each gene sequence is interpreted independently of all other gene sequences; however, variants in different genes may sometimes interact to cause or modify a typically monogenic disease phenotype. It cannot be excluded that pathogenic variants were missed due to limitations inherent in the methodologies used here. In addition, the presence of an inherited cancer syndrome due to a different genetic cause can also not be ruled out. Any interpretation given here should be clinically correlated with available information about presentation and relevant family history of the patient.
This test was developed, and its performance characteristics determined, by LabCorp. It has not been cleared or approved by the US Food and Drug Administration (FDA).
Next generation sequencing, array-based comparative genomic hybridization (aCGH), and multiplex ligation-dependent probe amplification (MLPA) platforms. The entire coding regions, as well as all flanking noncoding regions, of 25 cancer genes known to be involved in the development and progression of cancers are analyzed by next generation sequencing. Flanking regions for all genes include +/– 20 bp and +/– 10 bp. Copy number variations are assessed by aCGH or MLPA to detect deletions and duplications. BRCA1 and BRCA2 genes are not included in this test.
Blood is collected by routine phlebotomy.
Causes for Rejection
Frozen specimen; leaking tube; clotted specimen; grossly hemolyzed specimen; incorrect anticoagulant
Test orders must include an attestation that the provider has the patient's informed consent for genetic testing. See sample physician office consent form (Informed Consent for VistaSeq℠) in Related Documents. A Hereditary Cancer Clinical Questionnaire also should be submitted with specimens. Contact CMBP genetics services at 800-345-4363 to coördinate testing.
|Order Code||Order Code Name||Order Loinc||Result Code||Result Code Name||UofM||Result LOINC|
|481240||VistaSeq Hered Cancer w/o BRCA||481239||Specimen Type||31208-2|
|481240||VistaSeq Hered Cancer w/o BRCA||481234||Preauthorization||N/A|
|481240||VistaSeq Hered Cancer w/o BRCA||481246||Result Summary||51968-6|
|481240||VistaSeq Hered Cancer w/o BRCA||481247||Result and Interpretation||69548-6|
|481240||VistaSeq Hered Cancer w/o BRCA||481248||Recommendations||47042-7|
|481240||VistaSeq Hered Cancer w/o BRCA||481249||Additional Information||77202-0|
|481240||VistaSeq Hered Cancer w/o BRCA||481250||Methodology and Limitations||49549-9|
|481240||VistaSeq Hered Cancer w/o BRCA||481251||References||75608-0|
|481240||VistaSeq Hered Cancer w/o BRCA||481252||Director Review||72486-4|
|481240||VistaSeq Hered Cancer w/o BRCA||481253||51969-4|